Search

CN-121974841-A - Compounds for treating liver cancer

CN121974841ACN 121974841 ACN121974841 ACN 121974841ACN-121974841-A

Abstract

The present invention discloses a compound for treating liver cancer, which is named HCC-IN-919. The invention reveals the value of the compound HCC-IN-919 IN treating liver cancer for the first time, which not only provides a new thought for the research and development of anti-liver cancer drugs, but also lays a solid foundation for the new application of the compound HCC-IN-919 IN the field of anticancer, and provides a reference for the research and development of new drugs IN the future.

Inventors

  • ZHANG DEYU
  • GAO YUTING
  • Song Songze
  • WANG YANZHI

Assignees

  • 中国人民解放军北部战区总医院

Dates

Publication Date
20260505
Application Date
20260306

Claims (10)

  1. 1. A compound for treating liver cancer, which is characterized by having a structural formula shown in formula (I): Formula (I).
  2. 2. The compound of claim 1, further comprising pharmaceutically acceptable salts, pharmaceutically acceptable esters, isomers, polymorphs, solvates, prodrugs thereof.
  3. 3. Use of a compound according to claim 1 or 2 for the preparation of a medicament for the treatment of liver cancer.
  4. 4. The use according to claim 3, wherein the medicament further comprises a pharmaceutically acceptable carrier; Preferably, the pharmaceutically acceptable carrier comprises diluents, binders, surfactants, wetting agents, adsorption carriers, lubricants, fillers, disintegrants.
  5. 5. The use according to claim 3, wherein the pharmaceutical dosage form is selected from any one of injectable medicament, spray, capsule, tablet, pill, granule, powder, oral liquid; preferably, the mode of administration of the drug includes oral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal, mucosal and/or intraperitoneal injection.
  6. 6. The use of claim 3, wherein the medicament further comprises a second therapeutic agent; Preferably, the second therapeutic agent comprises sorafenib, lenvatinib, regorafenib, cabozantinib, atilizumab, bevacizumab, cisplatin, oxaliplatin, 5-fluorouracil, gemcitabine, capecitabine, or paclitaxel.
  7. 7. The use of a compound according to claim 1 or 2 for the preparation of an agent for inhibiting liver cancer cell activity, proliferation, migration, invasion and/or promoting apoptosis in liver cancer cells in vitro; preferably, the liver cancer cells comprise MHCC-97H, MHCC-97L, hepG2, SMMC-7721; preferably, the liver cancer cell is MHCC-97H.
  8. 8. A method for inhibiting the activity, proliferation, migration, invasion and/or promoting apoptosis of liver cancer cells for in vitro non-therapeutic purposes, which comprises the steps of treating liver cancer cells with an effective amount of the compound of claim 1 or 2 or a pharmaceutical composition comprising an effective amount of the compound of claim 1 or 2; preferably, the liver cancer cells comprise MHCC-97H, MHCC-97L, hepG2, SMMC-7721; preferably, the liver cancer cell is MHCC-97H.
  9. 9. A system for inhibiting the activity, proliferation, migration, invasion and/or promoting apoptosis of a liver cancer cell, comprising a treatment unit for treating a liver cancer cell with an effective amount of a compound of claim 1 or 2 or a pharmaceutical composition comprising an effective amount of a compound of claim 1 or 2; preferably, the liver cancer cells comprise MHCC-97H, MHCC-97L, hepG2, SMMC-7721; preferably, the liver cancer cell is MHCC-97H.
  10. 10. Use of a compound according to claim 1 or 2 for screening a medicament for treating liver cancer.

Description

Compounds for treating liver cancer Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to a compound for treating liver cancer. Background Liver cancer is one of the malignant tumors with higher morbidity and mortality in the global area. According to the global cancer statistics report issued by the international cancer research institution, the incidence rate of liver cancer is in the front of common malignant tumors, and the death rate is in the third place of cancer-related death causes. The disease burden of liver cancer is especially heavy due to the high prevalence of hepatitis b and c virus infections, and the combined effects of aflatoxin exposure, alcohol consumption, obesity, etc. The liver cancer is hidden, the early symptoms are not obvious, most patients are in middle and late stages when they are diagnosed, and the best opportunity for radical treatment such as surgical excision or liver transplantation is missed. For patients with unresectable advanced liver cancer, the traditional treatment means such as systemic chemotherapy has limited curative effect and obvious toxic and side effects, and cannot meet clinical requirements. In recent years, the advent of molecular targeted drugs and immune checkpoint inhibitors brings new breakthrough for the treatment of advanced liver cancer, multi-kinase inhibitors represented by sorafenib and lenvatinib, and immune combination therapies such as actlizumab and bevacizumab, and the survival time of patients is prolonged to a certain extent. However, these treatments still face challenges such as increasingly pronounced resistance problems, from which it is difficult for most patients to obtain a long lasting benefit. In view of the high incidence rate and high mortality rate of liver cancer and the limitations of the existing treatment means in terms of curative effect, drug resistance and safety, the molecular mechanism of occurrence and development of liver cancer is deeply explored, and the development of small molecular compounds with new action mechanisms and new chemical structures has become an urgent need and important direction in the field of research and development of liver cancer drugs. Disclosure of Invention In order to make up the defects of the prior art, the invention aims to provide a novel compound for treating liver cancer. In order to achieve the above purpose, the present invention adopts the following technical scheme: in a first aspect, the present invention provides a compound for use in the treatment of liver cancer. Further, the structural formula of the compound is shown as a formula (I): Formula (I). IN the present invention, the compound represented by formula (I) is named HCC-IN-919, its molecular formula is C 26H22N2O2, molecular mass is 394.47, and the compound is named 13- (2-toluidinomethyl) -9,10-dihydro-9,10- [3,4] pyrrosidinoanthracene-12, 14-dione. Further, the compounds also include pharmaceutically acceptable salts, pharmaceutically acceptable esters, isomers, polymorphs, solvates, prodrugs thereof. In the present application, the compound may be the compound itself or a pharmaceutically acceptable salt form of the compound. The pharmaceutically acceptable salts refer to acid salts formed with inorganic and/or organic acids and basic salts formed with inorganic and/or organic bases. In addition, when the compound contains a basic moiety (such as, but not limited to, pyridine or imidazole) and an acidic moiety (such as, but not limited to, carboxylic acid), a zwitterion may be formed and included in the pharmaceutically acceptable salts of the present application. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, but other salts are also useful. Pharmaceutically acceptable salts of the compounds may be formed, for example, by reacting the compound with an amount of an acid or base in a medium, such as one in which the salt precipitates or an aqueous medium (lyophilization after reaction). Specific pharmaceutically acceptable salts include those salts which are, within the scope of sound medical judgment, suitable for contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit or risk ratio. Pharmaceutically acceptable salts (pharmaceutically acceptable salts) are well known in the art. Pharmaceutically acceptable salts of the compounds of the application include salts derived from suitable inorganic and organic acids and inorganic and organic bases. In some embodiments, pharmaceutically acceptable esters refer to esters of hydroxyl groups present in the compounds provided herein with an appropriate acid (e.g., carboxylic acid or oxygen-containing mineral acid). Suitable esters include, but are not limited to, formate, acetate, propionate, butyrate, acrylate, ethylsuccinate, hard fatty acid ester, or palm